Does metformin reduce the risk of new-onset atrial fibrillation in patients with type 2 diabetes compared to other hypoglycemic agents?
Metformin use in patients with type 2 diabetes is associated with a reduced risk of developing new-onset atrial fibrillation, though this protective effect attenuates with age.
Metformin is associated with a lower risk of new-onset AF among patients with T2DM compared to other hypoglycemic agents. Furthermore, age-related attenuation of this association was observed, with older patients with T2DM showing a weaker association.
Vempati et al. (Wed,) studied this question.